» Articles » PMID: 37506095

Psychosocial Impact at the Time of a Rare Disease Diagnosis

Overview
Journal PLoS One
Date 2023 Jul 28
PMID 37506095
Authors
Affiliations
Soon will be listed here.
Abstract

Over half of all persons with rare diseases (RDs) in Spain experience diagnostic delay (DD) but little is known about its consequences. This study therefore aimed to analyze the psychological impact of obtaining a diagnosis of an RD, and to ascertain what social determinants are influenced and what the personal consequences are, according to whether or not patients experienced DD. Data were obtained from a purpose-designed form completed by persons registered at the Spanish Rare Diseases Patient Registry. The following were performed: a descriptive analysis; a principal component analysis (PCA); and logistic regressions. Results revealed that while searching for a diagnosis, people who experienced DD were more in need of psychological care than those diagnosed in less than one year (36.2% vs 23.2%; p = 0.002; n = 524). The PCA identified three principal components, i.e., psychological effects, social implications, and functional impact. Reducing DD would improve psychological effects, such as irritability (OR 3.6; 95%CI 1.5-8.5), frustration (OR 3.4; 95%CI 1.7-7.1) and concentration on everyday life (OR 3.3; 95%CI 1.4-7.7). The influence of the social implications and functional repercussions of the disease was greater in persons with DD (scores of 22.4 vs 20 and 10.6 vs 9.4, respectively) in terms of the difficulty in explaining symptoms to close friends and family (3.3 vs 2.9), and loss of independence (3.3 vs 2.9). In conclusion, this is the first study to analyze the psychosocial impact of diagnosis of RDs in Spain and one of few to assess it in the patients themselves, based on data drawn from a purpose-designed form from a national registry open to any RD. People affected by RDs who underwent DD experienced greater psychosocial impact than did those who were diagnosed within the space of one year.

Citing Articles

A global survey about undiagnosed rare diseases: perspectives, challenges, and solutions.

Baldovino S, Sciascia S, Carta C, Salvatore M, Cellai L, Ferrari G Front Public Health. 2025; 13:1510818.

PMID: 40078755 PMC: 11897027. DOI: 10.3389/fpubh.2025.1510818.


Capturing Real-World Rare Disease Patient Journeys: Are Current Methodologies Sufficient for Informed Healthcare Decisions?.

Cribbs K, Blackmore L, Banks A, Kim D, Lahue B J Eval Clin Pract. 2025; 31(1):e70010.

PMID: 39960234 PMC: 11831961. DOI: 10.1111/jep.70010.


A community-centric model for conference co-creation: the world conference on CDG for patients, families and professionals.

Francisco R, Pascoal C, Granjo P, De Freitas C, Videira P, Dos Reis Ferreira V Res Involv Engagem. 2024; 10(1):107.

PMID: 39443988 PMC: 11515494. DOI: 10.1186/s40900-024-00641-8.


Uncertainties of healthcare professionals and informal caregivers in rare diseases: A systematic review.

Zybarth D, Inhestern L, Otto R, Bergelt C Heliyon. 2024; 10(19):e38677.

PMID: 39403533 PMC: 11471567. DOI: 10.1016/j.heliyon.2024.e38677.


Spinal muscular atrophy carrier screening program: awareness and attitude of healthcare professionals in Turkey.

Muge Celik K, Kose C, Kaya D, Tekin K, Silan F J Community Genet. 2024; 15(6):665-672.

PMID: 39392569 PMC: 11645347. DOI: 10.1007/s12687-024-00737-4.


References
1.
Spillmann R, McConkie-Rosell A, Pena L, Jiang Y, Schoch K, Walley N . A window into living with an undiagnosed disease: illness narratives from the Undiagnosed Diseases Network. Orphanet J Rare Dis. 2017; 12(1):71. PMC: 5392939. DOI: 10.1186/s13023-017-0623-3. View

2.
van der Kloot W, Hamdy N, Hafkemeijer L, den Dulk F, Chotkan S, van Emmerik A . The psychological burden of an initially unexplained illness: patients with sternocostoclavicular hyperostosis before and after delayed diagnosis. Health Qual Life Outcomes. 2010; 8:97. PMC: 2954978. DOI: 10.1186/1477-7525-8-97. View

3.
Jaeger G, Rojvik A, Berglund B . Participation in society for people with a rare diagnosis. Disabil Health J. 2014; 8(1):44-50. DOI: 10.1016/j.dhjo.2014.07.004. View

4.
Zanello G, Chan C, Pearce D . Recommendations from the IRDiRC Working Group on methodologies to assess the impact of diagnoses and therapies on rare disease patients. Orphanet J Rare Dis. 2022; 17(1):181. PMC: 9078009. DOI: 10.1186/s13023-022-02337-2. View

5.
Sims R, Michaleff Z, Glasziou P, Thomas R . Consequences of a Diagnostic Label: A Systematic Scoping Review and Thematic Framework. Front Public Health. 2022; 9:725877. PMC: 8727520. DOI: 10.3389/fpubh.2021.725877. View